US9650639B2
(en)
|
2008-05-19 |
2017-05-16 |
Advaxis, Inc. |
Dual delivery system for heterologous antigens
|
EP2853269B1
(en)
|
2008-05-19 |
2019-05-01 |
Advaxis, Inc. |
Dual delivery system for heterologous antigens comprising a recombinant Listeria strain attenuated by mutation of dal/dat and deletion of ActA comprising a nucleic acid molecule encoding an listeriolysin O - prostate specific anigen fusion protein
|
US9017660B2
(en)
|
2009-11-11 |
2015-04-28 |
Advaxis, Inc. |
Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
|
CN108997498A
(zh)
|
2008-12-09 |
2018-12-14 |
霍夫曼-拉罗奇有限公司 |
抗-pd-l1抗体及它们用于增强t细胞功能的用途
|
US10016617B2
(en)
|
2009-11-11 |
2018-07-10 |
The Trustees Of The University Of Pennsylvania |
Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
|
WO2012138377A2
(en)
|
2010-10-01 |
2012-10-11 |
Trustees Of The University Of Pennsylvania |
The use of listeria vaccine vectors to reverse vaccine unresponsiveness in parasitically infected individuals
|
WO2012125551A1
(en)
|
2011-03-11 |
2012-09-20 |
Advaxis |
Listeria-based adjuvants
|
ES2671748T3
(es)
|
2011-07-21 |
2018-06-08 |
Tolero Pharmaceuticals, Inc. |
Inhibidores heterocíclicos de proteína quinasas
|
CN104411327A
(zh)
|
2012-03-12 |
2015-03-11 |
阿德瓦希斯公司 |
李斯特菌疫苗治疗以后的抑制细胞功能抑制
|
AR093984A1
(es)
*
|
2012-12-21 |
2015-07-01 |
Merck Sharp & Dohme |
Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
|
CA2905798C
(en)
|
2013-03-15 |
2023-01-24 |
Genentech, Inc. |
Biomarkers and methods of treating pd-1 and pd-l1 related conditions
|
WO2014165422A1
(en)
*
|
2013-04-02 |
2014-10-09 |
Merck Sharp & Dohme Corp. |
Immunohistochemical assay for detecting expression of programmed death ligand 1 (pd-l1) in tumor tissue
|
ES2788848T3
(es)
|
2013-09-06 |
2020-10-23 |
Aurigene Discovery Tech Ltd |
Derivados de 1,2,4-oxadiazol como inmunomoduladores
|
SG11201601679TA
(en)
|
2013-09-06 |
2016-04-28 |
Aurigene Discovery Tech Ltd |
1,3,4-oxadiazole and 1,3,4-thiadiazole derivatives as immunomodulators
|
JP6474412B2
(ja)
|
2013-09-06 |
2019-02-27 |
オーリジーン ディスカバリー テクノロジーズ リミテッドAurigene Discovery Technologies Limited |
免疫調節剤としての環式ペプチドミメティック化合物
|
SG11201601844TA
(en)
|
2013-09-13 |
2016-04-28 |
Beigene Ltd |
Anti-pd1 antibodies and their use as therapeutics and diagnostics
|
US10570204B2
(en)
|
2013-09-26 |
2020-02-25 |
The Medical College Of Wisconsin, Inc. |
Methods for treating hematologic cancers
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
ES2710211T3
(es)
|
2014-02-04 |
2019-04-23 |
Pfizer |
Combinación de un antagonista de PD-1 y un inhibidor de VEGFR para tratar el cáncer
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
CA2947932C
(en)
|
2014-05-29 |
2021-03-30 |
Spring Bioscience Corporation |
Pd-l1 antibodies and uses thereof
|
JP6526189B2
(ja)
|
2014-07-03 |
2019-06-05 |
ベイジーン リミテッド |
抗pd−l1抗体並びにその治療及び診断のための使用
|
WO2016007235A1
(en)
*
|
2014-07-11 |
2016-01-14 |
Genentech, Inc. |
Anti-pd-l1 antibodies and diagnostic uses thereof
|
KR20170052569A
(ko)
|
2014-07-18 |
2017-05-12 |
어드박시스, 인크. |
전립선암 치료용 pd-1 길항제 및 리스테리아 기반 백신의 병용
|
EP3171892B1
(en)
|
2014-07-22 |
2021-11-24 |
Apollomics Inc. |
Anti-pd-1 antibodies
|
JP6909153B2
(ja)
*
|
2014-08-05 |
2021-07-28 |
アポロミクス インコーポレイテッド |
抗pd−l1抗体
|
JP2017530950A
(ja)
*
|
2014-08-25 |
2017-10-19 |
ファイザー・インコーポレイテッド |
癌を処置するためのpd−1アンタゴニストおよびalk阻害剤の併用
|
US9535074B2
(en)
|
2014-09-08 |
2017-01-03 |
Merck Sharp & Dohme Corp. |
Immunoassay for soluble PD-L1
|
EP3925622A1
(en)
|
2014-09-13 |
2021-12-22 |
Novartis AG |
Combination therapies
|
EP4245376A3
(en)
|
2014-10-14 |
2023-12-13 |
Novartis AG |
Antibody molecules to pd-l1 and uses thereof
|
JP6908531B2
(ja)
*
|
2015-01-27 |
2021-07-28 |
ベンタナ メディカル システムズ, インコーポレイテッド |
アルデヒドに基づく固定溶液における長時間浸漬を用いる、組織試料固定法
|
DK3254110T3
(da)
|
2015-02-03 |
2020-05-18 |
Ventana Med Syst Inc |
Histokemisk test til vurdering af ekspression af programmeret død-ligand 1 (pd-l1)
|
US10202444B2
(en)
|
2015-02-24 |
2019-02-12 |
Rpeptide, Llc |
Anti-tau antibodies
|
RU2714233C2
(ru)
|
2015-02-26 |
2020-02-13 |
Мерк Патент Гмбх |
Ингибиторы pd-1 / pd-l1 для лечения рака
|
KR102662228B1
(ko)
|
2015-03-04 |
2024-05-02 |
머크 샤프 앤드 돔 코포레이션 |
암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
|
SG11201706872SA
(en)
|
2015-03-04 |
2017-09-28 |
Merck Sharp & Dohme |
Combination of a pd-1 antagonist and eribulin for treating cancer
|
EA034708B1
(ru)
|
2015-03-10 |
2020-03-10 |
Ауриджен Дискавери Текнолоджис Лимитед |
1,2,4-оксадиазольные и тиадиазольные соединения в качестве иммуномодуляторов
|
BR112017019559B1
(pt)
|
2015-03-13 |
2020-08-04 |
Cytomx Therapeutics, Inc |
Anticorpos anti-pdl1, anticorpos anti-pdl1 ativáveis, e métodos de uso destes
|
EP3280455A1
(en)
*
|
2015-04-07 |
2018-02-14 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Non-invasive imaging of tumor pd-l1 expression
|
US10144779B2
(en)
|
2015-05-29 |
2018-12-04 |
Agenus Inc. |
Anti-CTLA-4 antibodies and methods of use thereof
|
BR112017025562A2
(pt)
|
2015-05-29 |
2018-08-07 |
Merck Sharp & Dohme Corp. |
métodos para tratar câncer em um indivíduo e para tratar um indivíduo humano diagnosticado com câncer
|
EP3307777A4
(en)
*
|
2015-06-11 |
2019-02-13 |
Wuxi Biologics (Shanghai) Co. Ltd. |
NOVEL ANTI-PD-L1 ANTIBODIES
|
CA2989586A1
(en)
|
2015-06-16 |
2016-12-22 |
Pfizer, Inc. |
Pd-l1 antagonist combination treatments
|
KR20180036974A
(ko)
|
2015-07-16 |
2018-04-10 |
바이오엑셀 테라퓨틱스 인코포레이티드 |
면역조절을 이용하는 암의 치료를 위한 신규한 접근법
|
WO2017020291A1
(en)
*
|
2015-08-06 |
2017-02-09 |
Wuxi Biologics (Shanghai) Co. Ltd. |
Novel anti-pd-l1 antibodies
|
US11453697B1
(en)
|
2015-08-13 |
2022-09-27 |
Merck Sharp & Dohme Llc |
Cyclic di-nucleotide compounds as sting agonists
|
AR105654A1
(es)
|
2015-08-24 |
2017-10-25 |
Lilly Co Eli |
Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
|
EP3352858A4
(en)
|
2015-09-21 |
2019-04-17 |
Merck Sharp & Dohme Corp. |
ANTIBODIES THAT RELATE TO THE HUMAN FORM OF LIGAND-2 OF PROGRAMMED CELLULAR DEATH PROTEIN 1 (PD-L2), AND USE THEREOF
|
BR112018009064A8
(pt)
|
2015-11-17 |
2019-02-26 |
Jiangsu Hengrui Medicine Co |
anticorpo de pd-l1, fragmento de ligação ao antígeno do mesmo e aplicação médica do mesmo
|
WO2017087547A1
(en)
*
|
2015-11-17 |
2017-05-26 |
Oncomed Pharmaceuticals, Inc. |
Pd-l1-binding agents and uses thereof
|
AU2017207742B2
(en)
|
2016-01-11 |
2022-03-17 |
Inhibrx Biosciences, Inc. |
Multivalent and multispecific 41BB-binding fusion proteins
|
AU2017207318B2
(en)
*
|
2016-01-11 |
2023-12-07 |
Inhibrx Biosciences, Inc. |
Multivalent and multispecific OX40-binding fusion proteins
|
US10118963B2
(en)
*
|
2016-01-29 |
2018-11-06 |
Sorrento Therapeutics, Inc. |
Antigen binding proteins that bind PD-L1
|
US10465014B2
(en)
|
2016-03-04 |
2019-11-05 |
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. |
PDL-1 antibody, pharmaceutical composition thereof, and uses thereof
|
WO2017161976A1
(en)
*
|
2016-03-23 |
2017-09-28 |
Mabspace Biosciences (Suzhou) Co., Ltd |
Novel anti-pd-l1 antibodies
|
CN105968200B
(zh)
*
|
2016-05-20 |
2019-03-15 |
瑞阳(苏州)生物科技有限公司 |
抗人pd-l1人源化单克隆抗体及其应用
|
SG10201912563XA
(en)
|
2016-05-27 |
2020-02-27 |
Agenus Inc |
Anti-tim-3 antibodies and methods of use thereof
|
CA3027209C
(en)
*
|
2016-06-13 |
2022-08-16 |
I-Mab |
Anti-pd-l1 antibodies and uses thereof
|
WO2017218533A1
(en)
|
2016-06-13 |
2017-12-21 |
Torque Therapeutics, Inc. |
Methods and compositions for promoting immune cell function
|
EP3471754A1
(en)
|
2016-06-20 |
2019-04-24 |
Kymab Limited |
Anti-pd-l1 antibodies
|
WO2018029474A2
(en)
|
2016-08-09 |
2018-02-15 |
Kymab Limited |
Anti-icos antibodies
|
US9567399B1
(en)
|
2016-06-20 |
2017-02-14 |
Kymab Limited |
Antibodies and immunocytokines
|
WO2018007885A1
(en)
|
2016-07-05 |
2018-01-11 |
Beigene, Ltd. |
COMBINATION OF A PD-l ANTAGONIST AND A RAF INHIBITOR FOR TREATING CANCER
|
RU2764548C2
(ru)
|
2016-08-09 |
2022-01-18 |
Кимаб Лимитед |
Анти-icos антитела
|
EP4353747A3
(en)
|
2016-08-19 |
2024-06-26 |
BeiGene Switzerland GmbH |
Combination of zanubrutinib with an anti-cd20 or an anti-pd-1 antibody for use in treating cancer
|
CA3037230A1
(en)
*
|
2016-09-20 |
2018-03-29 |
Merck Patent Gmbh |
Diagnostic anti-pd-l1 antibody and use thereof
|
KR20190062515A
(ko)
|
2016-10-06 |
2019-06-05 |
화이자 인코포레이티드 |
암의 치료를 위한 아벨루맙의 투약 용법
|
KR20230133934A
(ko)
|
2016-10-11 |
2023-09-19 |
아게누스 인코포레이티드 |
항-lag-3 항체 및 이의 사용 방법
|
WO2018071792A1
(en)
|
2016-10-14 |
2018-04-19 |
Merck Sharp & Dohme Corp. |
Combination of a pd-1 antagonist and eribulin for treating urothelial cancer
|
WO2018083248A1
(en)
|
2016-11-03 |
2018-05-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
WO2018094275A1
(en)
|
2016-11-18 |
2018-05-24 |
Tolero Pharmaceuticals, Inc. |
Alvocidib prodrugs and their use as protein kinase inhibitors
|
AU2017373945A1
(en)
|
2016-12-07 |
2019-06-20 |
Agenus Inc. |
Antibodies and methods of use thereof
|
MX2019006340A
(es)
|
2016-12-07 |
2019-11-07 |
Agenus Inc |
Anticuerpos anti antígeno 4 del linfocito t citotóxico (ctla-4) y métodos de uso de los mismos.
|
WO2018111976A1
(en)
|
2016-12-14 |
2018-06-21 |
Janssen Biotech, Inc. |
Pd-l1 binding fibronectin type iii domains
|
EP3554561B1
(en)
|
2016-12-14 |
2023-06-28 |
Janssen Biotech, Inc. |
Cd137 binding fibronectin type iii domains
|
JP7104703B2
(ja)
|
2016-12-14 |
2022-07-21 |
ヤンセン バイオテツク,インコーポレーテツド |
Cd8a結合フィブロネクチンiii型ドメイン
|
WO2018132739A2
(en)
|
2017-01-13 |
2018-07-19 |
Agenus Inc. |
T cell receptors that bind to ny-eso-1 and methods of use thereof
|
WO2018137681A1
(en)
|
2017-01-25 |
2018-08-02 |
Beigene, Ltd. |
Crystalline forms of (s) -7- (1- (but-2-ynoyl) piperidin-4-yl) -2- (4-phenoxyphenyl) -4, 5, 6, 7-tetrahy dropyrazolo [1, 5-a] pyrimidine-3-carboxamide, preparation, and uses thereof
|
CN106699891B
(zh)
*
|
2017-01-25 |
2019-04-09 |
北京天广实生物技术股份有限公司 |
一种抗pd-l1抗体、其药物组合物及其用途
|
WO2018150224A1
(en)
|
2017-02-16 |
2018-08-23 |
Shenzhen Runshin Bioscience |
Anti-programmed death-ligand 1 (pd-l1) antibodies and therapeutic uses thereof
|
KR20240039221A
(ko)
*
|
2017-03-16 |
2024-03-26 |
알파인 이뮨 사이언시즈, 인코포레이티드 |
Pd-l1 리간드 변이체 면역조절 단백질 및 그의 용도
|
JP7166278B2
(ja)
|
2017-03-30 |
2022-11-07 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
がんの治療のための抗pd-l1抗体およびdna-pkインヒビターの併用
|
KR102629972B1
(ko)
|
2017-04-13 |
2024-01-29 |
아게누스 인코포레이티드 |
항-cd137 항체 및 이의 사용 방법
|
AR111651A1
(es)
|
2017-04-28 |
2019-08-07 |
Novartis Ag |
Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
|
MA50957A
(fr)
|
2017-05-01 |
2020-10-14 |
Agenus Inc |
Anticorps anti-tigit et leurs méthodes d'utilisation
|
CN107192817B
(zh)
*
|
2017-05-22 |
2018-04-24 |
广州华弘生物科技有限公司 |
一种用于检测pd-l1的快速检测试剂盒及其检测方法
|
KR20200016899A
(ko)
|
2017-06-01 |
2020-02-17 |
싸이톰스 테라퓨틱스, 인크. |
활성화가능 항-pdl1 항체, 및 이의 이용 방법
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
GB201709808D0
(en)
|
2017-06-20 |
2017-08-02 |
Kymab Ltd |
Antibodies
|
JP2020524694A
(ja)
|
2017-06-22 |
2020-08-20 |
ノバルティス アーゲー |
がんの処置における使用のためのIL−1β結合性抗体
|
EP3642240A1
(en)
|
2017-06-22 |
2020-04-29 |
Novartis AG |
Antibody molecules to cd73 and uses thereof
|
PE20200717A1
(es)
|
2017-06-22 |
2020-07-21 |
Novartis Ag |
Moleculas de anticuerpo que se unen a cd73 y usos de las mismas
|
WO2018235056A1
(en)
|
2017-06-22 |
2018-12-27 |
Novartis Ag |
IL-1BETA BINDING ANTIBODIES FOR USE IN THE TREATMENT OF CANCER
|
EP3645569A4
(en)
|
2017-06-26 |
2021-03-24 |
BeiGene, Ltd. |
IMMUNOTHERAPY FOR LIVER CELL CARCINOMA
|
EP3645037A1
(en)
|
2017-06-27 |
2020-05-06 |
Novartis AG |
Dosage regimens for anti-tim-3 antibodies and uses thereof
|
US20200172617A1
(en)
|
2017-07-20 |
2020-06-04 |
Novartis Ag |
Dosage regimens of anti-lag-3 antibodies and uses thereof
|
CN107286243A
(zh)
*
|
2017-07-27 |
2017-10-24 |
北京大学第医院 |
放射碘标记pd‑l1单克隆抗体及其制备方法与应用
|
AU2018326875A1
(en)
|
2017-09-04 |
2020-03-19 |
Agenus Inc. |
T cell receptors that bind to mixed lineage leukemia (MLL)-specific phosphopeptides and methods of use thereof
|
JP7196160B2
(ja)
|
2017-09-12 |
2022-12-26 |
スミトモ ファーマ オンコロジー, インコーポレイテッド |
Mcl-1阻害剤アルボシジブを用いた、bcl-2阻害剤に対して非感受性である癌の治療レジメン
|
WO2019061324A1
(en)
|
2017-09-29 |
2019-04-04 |
Curis Inc. |
CRYSTALLINE FORMS OF IMMUNOMODULATORS
|
KR20200068659A
(ko)
|
2017-10-11 |
2020-06-15 |
오리진 디스커버리 테크놀로지스 리미티드 |
3-치환된 1,2,4-옥사다이아졸의 결정질 형태
|
BR112020007046A2
(pt)
|
2017-10-19 |
2020-11-17 |
Debiopharm International S.A. |
produto de combinação para o tratamento do câncer
|
WO2019081983A1
(en)
|
2017-10-25 |
2019-05-02 |
Novartis Ag |
CD32B TARGETING ANTIBODIES AND METHODS OF USE
|
JP7378394B2
(ja)
|
2017-11-03 |
2023-11-13 |
オーリジーン オンコロジー リミテッド |
Tim-3およびpd-1経路の二重阻害剤
|
EP3706798A1
(en)
|
2017-11-06 |
2020-09-16 |
Aurigene Discovery Technologies Limited |
Conjoint therapies for immunomodulation
|
US11786529B2
(en)
|
2017-11-29 |
2023-10-17 |
Beigene Switzerland Gmbh |
Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors
|
BR112020010579A2
(pt)
|
2017-11-30 |
2020-11-10 |
Novartis Ag |
receptor de antígeno quimérico de alvejamento de bcma e usos do mesmo
|
GB201721338D0
(en)
|
2017-12-19 |
2018-01-31 |
Kymab Ltd |
Anti-icos Antibodies
|
US11629189B2
(en)
|
2017-12-19 |
2023-04-18 |
Kymab Limited |
Bispecific antibody for ICOS and PD-L1
|
WO2019129136A1
(zh)
*
|
2017-12-27 |
2019-07-04 |
信达生物制药(苏州)有限公司 |
抗pd-l1抗体及其用途
|
CN109970857B
(zh)
|
2017-12-27 |
2022-09-30 |
信达生物制药(苏州)有限公司 |
抗pd-l1抗体及其用途
|
AU2019205912A1
(en)
|
2018-01-03 |
2020-07-16 |
Palleon Pharmaceuticals Inc. |
Recombinant human sialidases, sialidase fusion proteins, and methods of using the same
|
CN112218651A
(zh)
|
2018-01-08 |
2021-01-12 |
诺华公司 |
用于与嵌合抗原受体疗法组合的免疫增强rna
|
CA3087105A1
(en)
|
2018-01-10 |
2019-07-18 |
Jiangsu Hengrui Medicine Co., Ltd. |
Pd-l1 antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
|
CN111936857B
(zh)
*
|
2018-01-15 |
2024-04-16 |
艾比克斯治疗私人有限公司 |
预测对疗法的反应的试剂和方法
|
AU2019215031A1
(en)
|
2018-01-31 |
2020-08-20 |
Novartis Ag |
Combination therapy using a chimeric antigen receptor
|
WO2019160956A1
(en)
|
2018-02-13 |
2019-08-22 |
Novartis Ag |
Chimeric antigen receptor therapy in combination with il-15r and il15
|
AU2019233596A1
(en)
|
2018-03-14 |
2020-10-08 |
Merck Patent Gmbh |
Compounds and uses thereof to treat tumors in a subject
|
US20210147547A1
(en)
|
2018-04-13 |
2021-05-20 |
Novartis Ag |
Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
|
MA52363A
(fr)
|
2018-04-26 |
2021-03-03 |
Agenus Inc |
Compositions peptidiques de liaison à une protéine de choc thermique (hsp) et leurs méthodes d'utilisation
|
SG11202010423VA
(en)
|
2018-05-04 |
2020-11-27 |
Merck Patent Gmbh |
COMBINED INHIBITION OF PD-1/PD-L1, TGFß AND DNA-PK FOR THE TREATMENT OF CANCER
|
TW202015726A
(zh)
|
2018-05-30 |
2020-05-01 |
瑞士商諾華公司 |
Entpd2抗體、組合療法、及使用該等抗體和組合療法之方法
|
US20210214459A1
(en)
|
2018-05-31 |
2021-07-15 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
EP3810109A4
(en)
|
2018-05-31 |
2022-03-16 |
Peloton Therapeutics, Inc. |
COMPOSITIONS AND METHODS FOR INHIBITING CD73
|
BR112020024351A2
(pt)
|
2018-06-01 |
2021-02-23 |
Novartis Ag |
moléculas de ligação contra bcma e usos das mesmas
|
US20210251994A1
(en)
|
2018-06-15 |
2021-08-19 |
Flagship Pioneering Innovations V, Inc. |
Increasing immune activity through modulation of postcellular signaling factors
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
CR20210001A
(es)
|
2018-07-10 |
2021-04-19 |
Novartis Ag |
Derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-diona y su uso en el tratamiento de trastornos dependientes de la proteina con dedos de zinc 2 de la familia ikaros (1kzf2)
|
TWI822815B
(zh)
*
|
2018-07-14 |
2023-11-21 |
財團法人生物技術開發中心 |
抗-人類pd-l1之抗體及其用途
|
WO2020020307A1
(en)
|
2018-07-25 |
2020-01-30 |
I-Mab Biopharma Co., Ltd. |
Anti-cd73 anti-pd-l1 bispecific antibodies
|
TW202019968A
(zh)
|
2018-08-13 |
2020-06-01 |
美商英伊布里克斯公司 |
Ox40結合多肽及其用途
|
CN116063519A
(zh)
*
|
2018-08-20 |
2023-05-05 |
北京强新生物科技有限公司 |
新型癌症免疫治疗抗体组合物
|
CA3114024A1
(en)
|
2018-09-26 |
2020-04-02 |
Merck Patent Gmbh |
Combination of a pd-1 antagonist, an atr inhibitor and a platinating agent for the treatment of cancer
|
WO2020089811A1
(en)
|
2018-10-31 |
2020-05-07 |
Novartis Ag |
Dc-sign antibody drug conjugates
|
EP3886842A1
(en)
|
2018-11-26 |
2021-10-06 |
Debiopharm International SA |
Combination treatment of hiv infections
|
EP3890749A4
(en)
|
2018-12-04 |
2022-08-03 |
Sumitomo Dainippon Pharma Oncology, Inc. |
CDK9 INHIBITORS AND POLYMORPHS THEREOF FOR USE AS CANCER TREATMENT AGENT
|
AU2019396360A1
(en)
|
2018-12-11 |
2021-05-27 |
Theravance Biopharma R&D Ip, Llc |
Naphthyridine and quinoline derivatives useful as ALK5 inhibitors
|
KR20210106437A
(ko)
|
2018-12-20 |
2021-08-30 |
노파르티스 아게 |
3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물
|
WO2020128613A1
(en)
|
2018-12-21 |
2020-06-25 |
Novartis Ag |
Use of il-1beta binding antibodies
|
AU2019408408A1
(en)
|
2018-12-21 |
2021-06-03 |
Valerio Therapeutics |
New conjugated nucleic acid molecules and their uses
|
WO2020128637A1
(en)
|
2018-12-21 |
2020-06-25 |
Novartis Ag |
Use of il-1 binding antibodies in the treatment of a msi-h cancer
|
JP2022516850A
(ja)
|
2018-12-21 |
2022-03-03 |
ノバルティス アーゲー |
骨髄異形成症候群の治療又は予防におけるIL-1β抗体の使用
|
US20220096518A1
(en)
|
2018-12-21 |
2022-03-31 |
Aim Immunotech Inc. |
Compositions and methods for cancer therapy
|
AU2019409139A1
(en)
|
2018-12-21 |
2021-06-03 |
Novartis Ag |
Use of IL-1β binding antibodies
|
WO2020128893A1
(en)
|
2018-12-21 |
2020-06-25 |
Pfizer Inc. |
Combination treatments of cancer comprising a tlr agonist
|
KR20210146290A
(ko)
|
2019-02-12 |
2021-12-03 |
스미토모 다이니폰 파마 온콜로지, 인크. |
헤테로시클릭 단백질 키나제 억제제를 포함하는 제제
|
US20220144807A1
(en)
|
2019-02-15 |
2022-05-12 |
Novartis Ag |
3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
EP3924055B1
(en)
|
2019-02-15 |
2024-04-03 |
Novartis AG |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
US11793802B2
(en)
|
2019-03-20 |
2023-10-24 |
Sumitomo Pharma Oncology, Inc. |
Treatment of acute myeloid leukemia (AML) with venetoclax failure
|
WO2020198077A1
(en)
|
2019-03-22 |
2020-10-01 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Compositions comprising pkm2 modulators and methods of treatment using the same
|
EP3962493A2
(en)
|
2019-05-03 |
2022-03-09 |
Flagship Pioneering Innovations V, Inc. |
Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
|
CN113874036A
(zh)
|
2019-05-24 |
2021-12-31 |
辉瑞公司 |
使用cdk抑制剂的联合治疗
|
CN114302878A
(zh)
|
2019-07-03 |
2022-04-08 |
大日本住友制药肿瘤公司 |
酪氨酸激酶非受体1(tnk1)抑制剂及其用途
|
WO2021024020A1
(en)
|
2019-08-06 |
2021-02-11 |
Astellas Pharma Inc. |
Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
|
US11680098B2
(en)
|
2019-08-30 |
2023-06-20 |
Agenus Inc. |
Antibodies that specifically bind human CD96
|
CN114502590A
(zh)
|
2019-09-18 |
2022-05-13 |
诺华股份有限公司 |
Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法
|
TW202124446A
(zh)
|
2019-09-18 |
2021-07-01 |
瑞士商諾華公司 |
與entpd2抗體之組合療法
|
AU2020350137A1
(en)
|
2019-09-20 |
2022-04-28 |
Merck Patent Gmbh |
Combination of a poxvirus encoding HPV polypeptides and IL-2 with an anti-PD-L1 antibody
|
US11781138B2
(en)
|
2019-10-14 |
2023-10-10 |
Aro Biotherapeutics Company |
FN3 domain-siRNA conjugates and uses thereof
|
JP2022551204A
(ja)
|
2019-10-14 |
2022-12-07 |
アロ・バイオセラピューティクス・カンパニー |
Cd71結合フィブロネクチンiii型ドメイン
|
BR112022007376A2
(pt)
|
2019-10-21 |
2022-07-05 |
Novartis Ag |
Terapias de combinação com venetoclax e inibidores de tim-3
|
WO2021079195A1
(en)
|
2019-10-21 |
2021-04-29 |
Novartis Ag |
Tim-3 inhibitors and uses thereof
|
TW202137984A
(zh)
|
2019-10-29 |
2021-10-16 |
日商衛材R&D企管股份有限公司 |
用於治療癌症之PD-1拮抗劑、VEGFR/FGFR/RET酪胺酸激酶抑制劑及CBP/β-連環蛋白抑制劑之組合
|
CN112745391B
(zh)
*
|
2019-10-30 |
2022-11-22 |
三优生物医药(上海)有限公司 |
Pd-l1结合分子
|
EP4061809A1
(en)
|
2019-11-22 |
2022-09-28 |
Theravance Biopharma R&D IP, LLC |
Substituted 1,5-naphthyridines or quinolines as alk5 inhibitors
|
WO2021102343A1
(en)
|
2019-11-22 |
2021-05-27 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Solid dose pharmaceutical composition
|
MX2022006578A
(es)
|
2019-12-17 |
2022-07-04 |
Pfizer |
Anticuerpos especificos para cd47, pd-l1 y sus usos.
|
US20230114107A1
(en)
|
2019-12-17 |
2023-04-13 |
Flagship Pioneering Innovations V, Inc. |
Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
|
WO2021123996A1
(en)
|
2019-12-20 |
2021-06-24 |
Novartis Ag |
Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
|
CN110964111B
(zh)
*
|
2019-12-25 |
2020-07-24 |
北京东方百泰生物科技有限公司 |
一种抗pd-l1单克隆抗体、其抗原结合片段及其应用
|
JP2023510393A
(ja)
|
2020-01-17 |
2023-03-13 |
ノバルティス アーゲー |
骨髄異形成症候群または慢性骨髄単球性白血病の処置に使用するためのtim-3阻害剤と低メチル化剤とを含む組合せ
|
AU2021213317A1
(en)
|
2020-01-28 |
2022-06-30 |
Centre National De La Recherche Scientifique |
Antisense oligonucleotide targeting LINC00518 for treating melanoma
|
EP4126824A1
(en)
|
2020-03-31 |
2023-02-08 |
Theravance Biopharma R&D IP, LLC |
Substituted pyrimidines and methods of use
|
WO2021249969A1
(en)
|
2020-06-10 |
2021-12-16 |
Merck Patent Gmbh |
Combination product for the treatment of cancer diseases
|
EP4165041A1
(en)
|
2020-06-10 |
2023-04-19 |
Theravance Biopharma R&D IP, LLC |
Naphthyridine derivatives useful as alk5 inhibitors
|
AR122644A1
(es)
|
2020-06-19 |
2022-09-28 |
Onxeo |
Nuevas moléculas de ácido nucleico conjugado y sus usos
|
CN115916199A
(zh)
|
2020-06-23 |
2023-04-04 |
诺华股份有限公司 |
包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案
|
EP4172323A1
(en)
|
2020-06-29 |
2023-05-03 |
Flagship Pioneering Innovations V, Inc. |
Viruses engineered to promote thanotransmission and their use in treating cancer
|
US20230250173A1
(en)
|
2020-07-01 |
2023-08-10 |
Pfizer Inc. |
Biomarkers for pd-1 axis binding antagonist therapy
|
AU2021306613A1
(en)
|
2020-07-07 |
2023-02-02 |
BioNTech SE |
Therapeutic RNA for HPV-positive cancer
|
US20230271940A1
(en)
|
2020-08-03 |
2023-08-31 |
Novartis Ag |
Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
CN112079928B
(zh)
*
|
2020-09-19 |
2023-08-01 |
北京华大蛋白质研发中心有限公司 |
一种抗pd-l1的单克隆抗体
|
KR20230104651A
(ko)
|
2020-11-06 |
2023-07-10 |
노파르티스 아게 |
Cd19 결합 분자 및 이의 용도
|
TW202237119A
(zh)
|
2020-12-10 |
2022-10-01 |
美商住友製藥腫瘤公司 |
Alk﹘5抑制劑和彼之用途
|
WO2022135667A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Therapeutic rna for treating cancer
|
WO2022135666A1
(en)
|
2020-12-21 |
2022-06-30 |
BioNTech SE |
Treatment schedule for cytokine proteins
|
TW202245808A
(zh)
|
2020-12-21 |
2022-12-01 |
德商拜恩迪克公司 |
用於治療癌症之治療性rna
|
EP4274614A1
(en)
*
|
2021-01-06 |
2023-11-15 |
Palleon Pharmaceuticals Inc. |
Anti-pd-l1 antibodies and fusion proteins thereof
|
JP2024505049A
(ja)
|
2021-01-29 |
2024-02-02 |
ノバルティス アーゲー |
抗cd73及び抗entpd2抗体のための投与方式並びにその使用
|
JP2024511373A
(ja)
|
2021-03-18 |
2024-03-13 |
ノバルティス アーゲー |
がんのためのバイオマーカーおよびその使用
|
TW202304506A
(zh)
|
2021-03-25 |
2023-02-01 |
日商安斯泰來製藥公司 |
涉及抗claudin 18.2抗體的組合治療以治療癌症
|
US20220325287A1
(en)
|
2021-03-31 |
2022-10-13 |
Flagship Pioneering Innovations V, Inc. |
Thanotransmission polypeptides and their use in treating cancer
|
CN113087796B
(zh)
*
|
2021-04-02 |
2022-03-18 |
河南省肿瘤医院 |
一种抗pd-l1抗体及其应用
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途
|
US20240182572A1
(en)
|
2021-04-09 |
2024-06-06 |
Ose Immunotherapeutics |
Scaffold for bifunctional molecules comprising pd-1 or cd28 and sirp binding domains
|
AU2022253351A1
(en)
|
2021-04-09 |
2023-10-12 |
Ose Immunotherapeutics |
New scaffold for bifunctional molecules with improved properties
|
TW202309022A
(zh)
|
2021-04-13 |
2023-03-01 |
美商努法倫特公司 |
用於治療具egfr突變之癌症之胺基取代雜環
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
WO2022243378A1
(en)
|
2021-05-18 |
2022-11-24 |
Kymab Limited |
Uses of anti-icos antibodies
|
WO2022251359A1
(en)
|
2021-05-26 |
2022-12-01 |
Theravance Biopharma R&D Ip, Llc |
Bicyclic inhibitors of alk5 and methods of use
|
GB202107994D0
(en)
|
2021-06-04 |
2021-07-21 |
Kymab Ltd |
Treatment of cancer
|
AU2022303363A1
(en)
|
2021-06-29 |
2024-01-18 |
Flagship Pioneering Innovations V, Inc. |
Immune cells engineered to promote thanotransmission and uses thereof
|
WO2023285552A1
(en)
|
2021-07-13 |
2023-01-19 |
BioNTech SE |
Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
|
WO2023051926A1
(en)
|
2021-09-30 |
2023-04-06 |
BioNTech SE |
Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists
|
WO2023057535A1
(en)
|
2021-10-06 |
2023-04-13 |
Genmab A/S |
Multispecific binding agents against pd-l1 and cd137 in combination with anti pd-1 antibodies for treating cancers
|
TW202333802A
(zh)
|
2021-10-11 |
2023-09-01 |
德商拜恩迪克公司 |
用於肺癌之治療性rna(二)
|
WO2023083439A1
(en)
|
2021-11-09 |
2023-05-19 |
BioNTech SE |
Tlr7 agonist and combinations for cancer treatment
|
WO2023111203A1
(en)
|
2021-12-16 |
2023-06-22 |
Onxeo |
New conjugated nucleic acid molecules and their uses
|
WO2023166420A1
(en)
|
2022-03-03 |
2023-09-07 |
Pfizer Inc. |
Multispecific antibodies and uses thereof
|
WO2023174210A1
(en)
|
2022-03-14 |
2023-09-21 |
Laekna Limited |
Combination treatment for cancer
|
WO2023214325A1
(en)
|
2022-05-05 |
2023-11-09 |
Novartis Ag |
Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
|
WO2023222854A1
(en)
|
2022-05-18 |
2023-11-23 |
Kymab Limited |
Uses of anti-icos antibodies
|
WO2024049949A1
(en)
|
2022-09-01 |
2024-03-07 |
Genentech, Inc. |
Therapeutic and diagnostic methods for bladder cancer
|
US20240174732A1
(en)
|
2022-10-05 |
2024-05-30 |
Flagship Pioneering Innovations V, Inc. |
Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer
|
WO2024115725A1
(en)
|
2022-12-01 |
2024-06-06 |
BioNTech SE |
Multispecific antibody against cd40 and cd137 in combination therapy with anti-pd1 ab and chemotherapy
|
WO2024126457A1
(en)
|
2022-12-14 |
2024-06-20 |
Astellas Pharma Europe Bv |
Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors
|